ICYMI: FDA Clears New Drug Application and Grants Priority Review for Potential Ehlers-Danlos Syndrome Drug
frolicsomepl / Pixabay

ICYMI: FDA Clears New Drug Application and Grants Priority Review for Potential Ehlers-Danlos Syndrome Drug

According to a story from BioPortfolio, the pharmaceutical company Acer Therapeutics, Inc., recently announced the company's New Drug Application (NDA) has been accepted by the US Food and Drug Administration…

Continue Reading ICYMI: FDA Clears New Drug Application and Grants Priority Review for Potential Ehlers-Danlos Syndrome Drug

Rising Cost of Drug Development isn’t Slowing Down Researchers Working to Uncover Novel Therapies for Rare Diseases

Every day the scientific community makes progress in the study of rare disease. Research in the field has advanced exponentially in recent years and we're starting to see more treatments…

Continue Reading Rising Cost of Drug Development isn’t Slowing Down Researchers Working to Uncover Novel Therapies for Rare Diseases
Pliant Announces Phase 1 Clinical Study Evaluating Anti-Fibrotic Agent PLN-74809
Source: Pixabay

Pliant Announces Phase 1 Clinical Study Evaluating Anti-Fibrotic Agent PLN-74809

Pliant Therapeutics, Inc., a biotechnology company specializing in developing and commercializing treatments for fibrotic diseases, announced on January 3, 2019 through PRNewswire, that it has initiated a Phase 1 first-in-human…

Continue Reading Pliant Announces Phase 1 Clinical Study Evaluating Anti-Fibrotic Agent PLN-74809
Safety Data Looks Good in Phase 3 Trial of Potential Pulmonary Arterial Hypertension Drug
DarkoStojanovic / Pixabay

Safety Data Looks Good in Phase 3 Trial of Potential Pulmonary Arterial Hypertension Drug

According to a story from BioSpace, the biopharmaceutical company Liquidia Technologies, Inc., has recently released interim safety data for its open label Phase 3 clinical trial testing LIQ861. This data…

Continue Reading Safety Data Looks Good in Phase 3 Trial of Potential Pulmonary Arterial Hypertension Drug

Unique Class of Drugs Shows Potential in Treating Idiopathic Pulmonary Fibrosis

According to a story from Medical Xpress, a collaborative team of scientists from UT Health San Antonio, the Mayo Clinic, and the Wake Forest School of Medicine, have recently released…

Continue Reading Unique Class of Drugs Shows Potential in Treating Idiopathic Pulmonary Fibrosis
Girl With Extremely Rare Juvenile Amyotrophic Lateral Sclerosis Keeps Positive Attitude
SarahRichterArt / Pixabay

Girl With Extremely Rare Juvenile Amyotrophic Lateral Sclerosis Keeps Positive Attitude

According to a story from king5.com, nine-year-old Taylor Futch's smile has always been able to captivate those around her. Unfortunately, Taylor's smile is often the extent of her ability to…

Continue Reading Girl With Extremely Rare Juvenile Amyotrophic Lateral Sclerosis Keeps Positive Attitude
Experimental Drug Displays Potential for Treating Intrahepatic Cholangiocarcinoma in Clinical Trial
jarmoluk / Pixabay

Experimental Drug Displays Potential for Treating Intrahepatic Cholangiocarcinoma in Clinical Trial

According to a story from Business Wire, Basilea Pharmaceutica, Ltd., a partner of ArQule, Inc., recently released interim results from its Phase 2 clinical trial testing the company's investigational drug…

Continue Reading Experimental Drug Displays Potential for Treating Intrahepatic Cholangiocarcinoma in Clinical Trial

Editor’s Choice: CIDP Athletes, Parents Turned Researchers, and Commonplace Medicines with Concerning Correlations

Happy Thursday! We hope everyone's new year is off to a good start. If you're in need of some inspiration, we're highlighting a story of a woman with CIDP accomplishing…

Continue Reading Editor’s Choice: CIDP Athletes, Parents Turned Researchers, and Commonplace Medicines with Concerning Correlations

Stanford PhD Candidate Creates Platform for Parkinson’s Disease Patients to Share Their Story with Researchers

"Beyond research motivation, I want to give a voice to the disease to help researchers empathize and further understand who all their hard work is going toward." These are words from…

Continue Reading Stanford PhD Candidate Creates Platform for Parkinson’s Disease Patients to Share Their Story with Researchers
Clinical Trial Will Test Combination Treatment for Erdheim-Chester Disease
stevepb / Pixabay

Clinical Trial Will Test Combination Treatment for Erdheim-Chester Disease

A new clinical trial which will test a two-part combination treatment for Erdheim-Chester disease was recently added to the clinicaltrials.gov website. This trial will be specifically for patients with BRAF…

Continue Reading Clinical Trial Will Test Combination Treatment for Erdheim-Chester Disease
Extension Study for Prader-Willi Syndrome Initiated After Completion of Phase 2a Trial
source: pixabay.com

Extension Study for Prader-Willi Syndrome Initiated After Completion of Phase 2a Trial

Prader-Willi Syndrome (PWS) is caused by deleted genes on chromosome 15. This results in improper signaling of satiety, leading to obesity. Individuals with the condition can suffer from respiratory/cardiac disease, gastric…

Continue Reading Extension Study for Prader-Willi Syndrome Initiated After Completion of Phase 2a Trial
A Team From The University of Southern California Take on Single Father’s Amyotrophic Lateral Sclerosis
ljcor / Pixabay

A Team From The University of Southern California Take on Single Father’s Amyotrophic Lateral Sclerosis

According to a story from the USC News, a team of doctors with the University of Southern California (USC) ALS Clinic are doing their best to help Shaun Kalpakoff, a…

Continue Reading A Team From The University of Southern California Take on Single Father’s Amyotrophic Lateral Sclerosis
Nonprofit Organization Predicts Gene Therapy to be Most Cost Effective Treatment for Spinal Muscular Atrophy
qimono / Pixabay

Nonprofit Organization Predicts Gene Therapy to be Most Cost Effective Treatment for Spinal Muscular Atrophy

According to a story from physiciansweekly.com, a recent report from the Institute for Clinical and Economic Review (ICER) suggests that, pending more data about overall price and longterm success rates,…

Continue Reading Nonprofit Organization Predicts Gene Therapy to be Most Cost Effective Treatment for Spinal Muscular Atrophy